Class information for:
Level 1: CD20//RITUXIMAB//OBINUTUZUMAB

Basic class information
Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
10 4 IMMUNOLOGY//TRANSPLANTATION//RHEUMATOLOGY 1369268
97 3       EPSTEIN BARR VIRUS//HEMATOLOGY//LYMPHOMA 77599
90 2             CHRONIC LYMPHOCYTIC LEUKEMIA//MANTLE CELL LYMPHOMA//FOLLICULAR LYMPHOMA 26562
12218 1                   CD20//RITUXIMAB//OBINUTUZUMAB 952

Terms with highest relevance score


rank Category termType chi_square shrOfCwithTerm shrOfTermInClass termInClass
1 CD20 authKW 1201889 15% 25% 145
2 RITUXIMAB authKW 331623 22% 5% 210
3 OBINUTUZUMAB authKW 291292 2% 40% 22
4 OFATUMUMAB authKW 196542 3% 25% 24
5 GA101 authKW 170249 1% 86% 6
6 CD20 EXPRESSION authKW 148967 1% 75% 6
7 RITUXIMAB RESISTANCE authKW 147460 1% 64% 7
8 ADCC authKW 111436 4% 8% 40
9 COMPLEMENT DEPENDENT CYTOTOXICITY authKW 107469 2% 19% 17
10 EA3853 address 99313 0% 100% 3

Web of Science journal categories


chi_square_rank Category chi_square shrOfCwithTerm shrOfTermInClass termInClass
1 Hematology 7365 27% 0% 257
2 Oncology 4661 37% 0% 352
3 Immunology 2465 25% 0% 240
4 Medicine, Research & Experimental 300 8% 0% 74
5 Pharmacology & Pharmacy 61 7% 0% 70
6 Rheumatology 46 2% 0% 15
7 Cell Biology 42 6% 0% 53
8 Pathology 36 2% 0% 23
9 Biochemical Research Methods 23 3% 0% 25
10 Biotechnology & Applied Microbiology 13 3% 0% 30

Address terms


chi_square_rank term chi_square shrOfCwithTerm shrOfTermInClass termInClass
1 EA3853 99313 0% 100% 3
2 CELLULAR GENE THER Y G LANZANI 68962 1% 42% 5
3 TENOVUS CANC SCI 68962 1% 42% 5
4 TARGETED THER Y GRPPATERSON CANC 66209 0% 100% 2
5 UNICO COORDINADOR ABLAC IMPLANTE PROV BUENO 66209 0% 100% 2
6 MOL IMMUNOHAEMATOL 66205 0% 50% 4
7 TENOVUS 56849 2% 11% 16
8 CELLULAR THER Y G LANZANI 55167 1% 33% 5
9 DAVID EVANS MED 55167 1% 33% 5
10 OLYMPUS BIOIMAGING 49654 0% 50% 3

Journals


chi_square_rank term chi_square shrOfCwithTerm shrOfTermInClass termInClass
1 BLOOD 6180 9% 0% 81
2 MABS 5980 1% 2% 12
3 LEUKEMIA & LYMPHOMA 2854 3% 0% 26
4 CLINICAL CANCER RESEARCH 2758 4% 0% 36
5 JOURNAL OF IMMUNOLOGY 2358 7% 0% 63
6 HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 1876 1% 1% 10
7 JOURNAL OF IMMUNOTHERAPY 1555 1% 1% 9
8 LEUKEMIA 1521 2% 0% 19
9 ONCOIMMUNOLOGY 1375 1% 1% 7
10 COMPLEMENT 1180 0% 4% 1

Author Key Words


chi_square_rank term chi_square shrOfCwithTerm shrOfTermInClass termInClass LCSH search Wikipedia search
1 CD20 1201889 15% 25% 145 Search CD20 Search CD20
2 RITUXIMAB 331623 22% 5% 210 Search RITUXIMAB Search RITUXIMAB
3 OBINUTUZUMAB 291292 2% 40% 22 Search OBINUTUZUMAB Search OBINUTUZUMAB
4 OFATUMUMAB 196542 3% 25% 24 Search OFATUMUMAB Search OFATUMUMAB
5 GA101 170249 1% 86% 6 Search GA101 Search GA101
6 CD20 EXPRESSION 148967 1% 75% 6 Search CD20+EXPRESSION Search CD20+EXPRESSION
7 RITUXIMAB RESISTANCE 147460 1% 64% 7 Search RITUXIMAB+RESISTANCE Search RITUXIMAB+RESISTANCE
8 ADCC 111436 4% 8% 40 Search ADCC Search ADCC
9 COMPLEMENT DEPENDENT CYTOTOXICITY 107469 2% 19% 17 Search COMPLEMENT+DEPENDENT+CYTOTOXICITY Search COMPLEMENT+DEPENDENT+CYTOTOXICITY
10 HTM4 99313 0% 100% 3 Search HTM4 Search HTM4

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.

Classes with closest relation at Level 1


rank cluster_id2 link
1 2524 FOLLICULAR LYMPHOMA//RADIOIMMUNOTHERAPY//RITUXIMAB
2 22414 RITUXIMAB//B CELL DEPLETION//ARBITER
3 8467 AGALACTOSYL IGG//CHRISTIAN DOPPLER ANTIBODY ENGN//EFFECTOR FUNCTION
4 197 CHRONIC LYMPHOCYTIC LEUKEMIA//CLL//CHRONIC LYMPHOCYTIC LEUKAEMIA
5 3304 FC RECEPTOR//FC GAMMA RECEPTORS//FC GAMMA RECEPTOR
6 8446 BISPECIFIC ANTIBODY//BISPECIFIC ANTIBODIES//BISPECIFIC
7 21397 U396//HUMAN LEUKOCYTE ANTIGEN II//IMMEDIATE EARLY PROTEINS IE
8 18148 DACLIZUMAB//NEUROIMMUNOL DIS UNIT//ALEMTUZUMAB
9 14710 IDIOTYPE//IDIOTYPE VACCINATION//RELAY HYPOTHESIS
10 12413 ANTIBODY DRUG CONJUGATE//TRASTUZUMAB EMTANSINE//T DM1

Go to start page